TransMedics Group, Inc. - Common Stock (TMDX)

TransMedics (TMDX) is a top GARP stock with explosive revenue & earnings growth, strong profitability, and a reasonable valuation relative to its industry peers.

These stocks are crushing the market this year, and there is likely plenty of upside ahead.

TransMedics Group (NASDAQ: TMDX) has outperformed the market over the past 5 years by 37.76% on an annualized basis producing an average annual return of 52.39%. Currently, TransMedics Group has a market capitalization of $3.89 billion.

TransMedics (TMDX) is a top affordable growth stock with strong revenue & EPS growth, solid financial health, and a reasonable valuation in the organ transplant tech sector.

TransMedics (TMDX) shows explosive revenue & EPS growth, trading at a reasonable valuation given its strong position in the organ transplant tech market.

Affordable Growth investing balances strong revenue/earnings growth with fair pricing, as seen in TransMedics (TMDX), with high growth metrics, reasonable valuation, and stable finances.

TransMedics continues to lock in its status as the leader in organ transplant technology.

TransMedics Group shares are rising in Wednesday's after-hours session after the company reported financial results for the second quarter.

TransMedics reported second-quarter financial results that were considerably better than most investors had anticipated. Investors were also pleased that TransMedics increased its guidance for the full 2025 year.